An observational study evaluating Hemophilia A patients who have previously received Kovaltry for prophylaxis

What we are studying

A Multinational Phase IV Study Evaluating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for Routine Prophylaxis

Who is Eligible

  • Genders:
    • Men
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Inclusion - Currently on (started within 3 months of study enrollment) or plan to start prophylaxis therapy with KOVALTRY
  • Patients with no history of inhibitors Exclusion - Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A

What is involved

  • Medical history
  • Physical examination
  • Questionnaires
  • Patient event diary
  • And prophylaxis injection diary

Compensation

$25 per completed diary

Contact Information

Study Coordinator
Anita Smith
Email
ansmith@wakehealth.edu
Phone
336-716-2534
Principal Investigator
Katharine Batt, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.